Surgery is a possible next step if those therapies fail or there is structural damage
Arbitrary digital weigh-in mandates, with no explanation of use, based on outdated BMI standards, ignores the latest FDA guidance
Simes-Faria R, Daems M, Peacock HM, Declercq M, Willems A, Jones EAV, et al
They can help decide if the benefits are worth it and adjust your treatment
[12] Limited observational data suggest that naltrexone does not significantly increase major congenital anomalies, yet its use for weight management in pregnancy is discouraged because long-term neurodevelopmental outcomes remain unclear
A Phase I, single-dose study to evaluate the safety, tolerability, and pharmacokinetics of ASC43F, a fixed-dose combination oral tablet of ASC41, a thyroid hormone receptor Beta agonist, and ASC42, a farnesoid X receptor agonist in healthy subjects